We just need your registered Email Id
to sent your password reset
instructions.
You're doing something extraordinary. We'll keep you in the loop with our latest news and special offers. Please update your profile on a regular basis and be an active community member. Let others know we exist and together we can move medicine forward.
You are now registered within Modern Trials network. If we receive patient inquires within your zip code we will let you know. Be on the look out for an E-Mail from our team.
| NCT Id | NCT04107961 |
|---|---|
| Title | A Study to Assess Safety and Efficacy of a Leishmania Vaccine to Prevent Post Kala Azar Dermal Leishmaniasis (PKDL) |
| Condition | Post-kala-azar Dermal Leishmaniasis |
| StudyType | Interventional |
| Organization | University of York |
| Sponsor/Collaborators | University of York |
| Status | Not yet recruiting |
| Gender | All |
| AgeGroup | Child Adult |
| Location (with distance) | |
| Description | The LEISH3 trial is a randomised, controlled, double blind Phase II clinical trial to evaluate the safety and efficacy of vaccination with ChAd63-KH in the prevention of post-kala azar dermal leishmaniasis (PKDL) in Sudanese visceral leishmaniasis (VL) patients previously treated with sodium stibogluconate / paromomycin (SSG / PM). |
Your interest has been recorded and our team is working hard for you. We will contact you with further steps.